These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 13196179)

  • 21. Diethylstitboestrol in the treatment of inoperable carcinoma of the prostate: a preliminary report.
    MACKINNON KJ; NEARING TN; CARRUTHERS NC
    Can Med Assoc J; 1957 Dec; 77(11):1009-12. PubMed ID: 13489589
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of 200 cases of carcinoma of the prostate treated conservatively.
    SATTER EJ; WEAR JB
    Wis Med J; 1958 Sep; 57(9):327-9. PubMed ID: 13581738
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of prostate carcinoma with transurethral infiltrations of phosphorylated diethylstibesterol; preliminary report].
    ROTHAUGE CF
    Arztl Wochensch; 1958 Mar; 13(11):233-5. PubMed ID: 13533095
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cancer of the lung metastatic from the prostate; disappearance of the radiological images after diethylstilbestrol therapy].
    MEYER A; HINAUT G; LIOT F
    Bull Mem Soc Med Hop Paris; 1951 Oct 19-26; 67(27-28):1190-5. PubMed ID: 14925878
    [No Abstract]   [Full Text] [Related]  

  • 25. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolysis in patients with metastatic carcinoma of the prostate gland.
    DOLAZ EJ; DOLEHIDE RA; FRIEDMAN IA
    Ill Med J; 1955 Mar; 107(3):142-4. PubMed ID: 14353517
    [No Abstract]   [Full Text] [Related]  

  • 27. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 29. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
    Oh WK; Kantoff PW; Weinberg V; Jones G; Rini BI; Derynck MK; Bok R; Smith MR; Bubley GJ; Rosen RT; DiPaola RS; Small EJ
    J Clin Oncol; 2004 Sep; 22(18):3705-12. PubMed ID: 15289492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine inhibition as related to carcinoma of the prostate.
    VALK WL; OWENS RH
    J Urol; 1954 Sep; 72(3):516-24. PubMed ID: 13202240
    [No Abstract]   [Full Text] [Related]  

  • 31. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapeutic aspects in the treatment of prostatic cancer.
    HASCHE-KLUNDER R; WILMANNS H
    Br J Urol; 1957 Mar; 29(1):20-4. PubMed ID: 13413208
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical experience of hormone therapy to bone metastatic prostate cancer.
    Wakisaka M; Nomura K
    Int J Urol; 2006 May; 13(5):550-4. PubMed ID: 16771724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Initial experiments with the therapeutic applications of sexoclasia].
    WALLON H
    Scalpel (Brux); 1954 Oct; 107(44):1147-61. PubMed ID: 13225593
    [No Abstract]   [Full Text] [Related]  

  • 37. [New methods of treatment of prostatic carcinoma].
    HASCHE-KLUNDER R; GACA A
    Med Klin; 1955 Dec; 50(48):2032-5. PubMed ID: 13287784
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravenous and oral trial of stilboestrol diphosphate in prostatic carcinoma.
    TAYLOR JR
    Can Med Assoc J; 1959 Jun; 80(11):880-2. PubMed ID: 13662941
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
    Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical study of endocrine therapy in stage B and C prostate cancer].
    Uei T; Okazaki H; Nakamura T; Katou N; Suzuki K; Yamanaka H
    Hinyokika Kiyo; 2003 Nov; 49(11):639-43. PubMed ID: 14719450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.